184 related articles for article (PubMed ID: 31952544)
21. Subtle neuropsychiatric and neurocognitive changes in hereditary gelsolin amyloidosis (AGel amyloidosis).
Kantanen M; Kiuru-Enari S; Salonen O; Kaipainen M; Hokkanen L
PeerJ; 2014; 2():e493. PubMed ID: 25097823
[TBL] [Abstract][Full Text] [Related]
22. Clinical and genetical diagnosis of a case of Meretoja syndrome and frontotemporal lifting procedure.
Galindo-Bocero J; García-Martínez I; Portillo M; Hernando Acero I; García-González N
Arch Soc Esp Oftalmol (Engl Ed); 2022 Oct; 97(10):583-586. PubMed ID: 36114141
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Histopathological Features of Gelsolin Amyloidosis Associated with a Novel
Potrč M; Volk M; de Rosa M; Pižem J; Teran N; Jaklič H; Maver A; Drnovšek-Olup B; Bollati M; Vogelnik K; Hočevar A; Gornik A; Pfeifer V; Peterlin B; Hawlina M; Fakin A
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499149
[TBL] [Abstract][Full Text] [Related]
24. Ocular amyloid deposition in familial amyloidosis, Finnish: an analysis of native and variant gelsolin in Meretoja's syndrome.
Kivelä T; Tarkkanen A; Frangione B; Ghiso J; Haltia M
Invest Ophthalmol Vis Sci; 1994 Sep; 35(10):3759-69. PubMed ID: 8088963
[TBL] [Abstract][Full Text] [Related]
25. Neuromuscular pathology in hereditary gelsolin amyloidosis.
Kiuru-Enari S; Somer H; Seppäläinen AM; Notkola IL; Haltia M
J Neuropathol Exp Neurol; 2002 Jun; 61(6):565-71. PubMed ID: 12071640
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosis.
Rowczenio D; Tennent GA; Gilbertson J; Lachmann HJ; Hutt DF; Bybee A; Hawkins PN; Gillmore JD
Amyloid; 2014 Dec; 21(4):276-81. PubMed ID: 25342098
[TBL] [Abstract][Full Text] [Related]
27. Hereditary gelsolin amyloidosis (HGA): a neglected cause of bilateral progressive or recurrent facial palsy.
Sagnelli A; Piscosquito G; Di Bella D; Fadda L; Melzi L; Morico A; Ciano C; Taroni F; Facchetti D; Salsano E; Pareyson D
J Peripher Nerv Syst; 2017 Mar; 22(1):59-63. PubMed ID: 27982499
[TBL] [Abstract][Full Text] [Related]
28. Lattice corneal dystrophy type II: clinical, pathologic, and molecular study in a Spanish family.
Huerva V; Velasco A; Sánchez MC; Mateo AJ; Matías-Guiu X
Eur J Ophthalmol; 2007; 17(3):424-9. PubMed ID: 17534828
[TBL] [Abstract][Full Text] [Related]
29. A novel GSN variant outside the G2 calcium-binding domain associated with Amyloidosis of the Finnish type.
Mullany S; Souzeau E; Klebe S; Zhou T; Knight LSW; Qassim A; Berry EC; Marshall H; Hussey M; Dubowsky A; Breen J; Hassall MM; Mills RA; Craig JE; Siggs OM
Hum Mutat; 2021 Jul; 42(7):818-826. PubMed ID: 33973672
[TBL] [Abstract][Full Text] [Related]
30. Nanobody interaction unveils structure, dynamics and proteotoxicity of the Finnish-type amyloidogenic gelsolin variant.
Giorgino T; Mattioni D; Hassan A; Milani M; Mastrangelo E; Barbiroli A; Verhelle A; Gettemans J; Barzago MM; Diomede L; de Rosa M
Biochim Biophys Acta Mol Basis Dis; 2019 Mar; 1865(3):648-660. PubMed ID: 30625383
[TBL] [Abstract][Full Text] [Related]
31. Progressive cranial nerve involvement and grading of facial paralysis in gelsolin amyloidosis.
Pihlamaa T; Salmi T; Suominen S; Kiuru-Enari S
Muscle Nerve; 2016 May; 53(5):762-9. PubMed ID: 26422119
[TBL] [Abstract][Full Text] [Related]
32. The role of gelsolin domain 3 in familial amyloidosis (Finnish type).
Zorgati H; Larsson M; Ren W; Sim AYL; Gettemans J; Grimes JM; Li W; Robinson RC
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):13958-13963. PubMed ID: 31243148
[TBL] [Abstract][Full Text] [Related]
33. Clinical Features and Brain MRI Findings in Korean Patients with AGel Amyloidosis.
Cheong EN; Paik W; Choi YC; Lim YM; Kim H; Shim WH; Park HJ
Yonsei Med J; 2021 May; 62(5):431-438. PubMed ID: 33908214
[TBL] [Abstract][Full Text] [Related]
34. Myocardial tissue characterization in patients with hereditary gelsolin (AGel) amyloidosis using novel cardiovascular magnetic resonance techniques.
Lehmonen L; Kaasalainen T; Atula S; Mustonen T; Holmström M
Int J Cardiovasc Imaging; 2019 Feb; 35(2):351-358. PubMed ID: 30848402
[TBL] [Abstract][Full Text] [Related]
35. Familial amyloidotic polyneuropathy type IV--gelsolin amyloidosis.
Pihlamaa T; Suominen S; Kiuru-Enari S
Amyloid; 2012 Jun; 19 Suppl 1():30-3. PubMed ID: 22512621
[TBL] [Abstract][Full Text] [Related]
36. Corneal morphology and sensitivity in lattice dystrophy type II (familial amyloidosis, Finnish type).
Rosenberg ME; Tervo TM; Gallar J; Acosta MC; Müller LJ; Moilanen JA; Tarkkanen AH; Vesaluoma MH
Invest Ophthalmol Vis Sci; 2001 Mar; 42(3):634-41. PubMed ID: 11222521
[TBL] [Abstract][Full Text] [Related]
37. Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.
Solomon JP; Page LJ; Balch WE; Kelly JW
Crit Rev Biochem Mol Biol; 2012; 47(3):282-96. PubMed ID: 22360545
[TBL] [Abstract][Full Text] [Related]
38. Relation of gelsolin amyloidosis and periodontal health.
Juusela PL; Persson RG; Nieminen AR; Kiuru-Enari SM; Uitto VJ
Clin Oral Investig; 2015 Mar; 19(2):229-35. PubMed ID: 24852333
[TBL] [Abstract][Full Text] [Related]
39. Severe ocular involvement in hereditary gelsolin amyloidosis.
da Silva NFP; Beirão JNM
Porto Biomed J; 2021; 6(5):e146. PubMed ID: 34651091
[TBL] [Abstract][Full Text] [Related]
40. Gelsolin variant (Asn-187) in familial amyloidosis, Finnish type.
Ghiso J; Haltia M; Prelli F; Novello J; Frangione B
Biochem J; 1990 Dec; 272(3):827-30. PubMed ID: 2176481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
